
    
      Total Body Irradiation (TBI) continues to play an important role in myeloablative and
      non-myeloablative conditioning regimens for Allogeneic Stem Cell Transplant (ASCT). When TBI
      is used as part of a myeloablative regimen, it is combined with chemotherapy to eradicate
      malignant cells, as well as to immunosuppress the host to prevent rejection of donor
      hematopoietic progenitor cells (HPC).

      This study is a single-institution study to assess the safety of linac based VMAT TBI for
      myeablative sreatment in hematologic malignancies.
    
  